+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028: Segmented By Type (Biologics v/s Biosimilars), By Product Type, By Therapeutic Area, By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2028

  • PDF Icon

    Report

  • 116 Pages
  • December 2022
  • Region: Global
  • TechSci Research
  • ID: 5706788
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Global adalimumab market is expected to undergo significant growth during the forecast period, 2024-2028. The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNFα. Adalimumab are currently being marketed in over 60 countries around the world.

Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.

Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn’s disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.

Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.

Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.

Objective of the Study:

To analyse and forecast the market size of global adalimumab market.

To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.

To identify drivers and challenges for global adalimumab market.

To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.

To identify and analyse the profile of leading players operating in the global adalimumab market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, The research team sourced a list of adalimumab manufacturing companies across the globe. Subsequently, The research team conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies which could not be identified due to the limitations of secondary research.

The publisher calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. The research team sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.

Key Target Audience:

  • Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to adalimumab

Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Adalimumab Market, By Type:

  • Biologics
  • Biosimilar

Global Adalimumab Market, By Product Type:

  • Branded
  • Generics

Global Adalimumab Market, By Therapeutic Area:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Psoriasis
  • Crohn’s Disease
  • Others

Global Adalimumab Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Adalimumab Market, By End User:

  • Hospitals & Clinics
  • Home Healthcare
  • Others

Global Adalimumab Market, By Region:

  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • North America
  • United States
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global adalimumab market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

Profit margin analysis in case of direct and indirect sales channel.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
4.1. Adalimumab Demand, By Therapeutic Area
4.2. Adalimumab Demand, By Region
4.3. Adalimumab Demand, By Gender
4.4. Adalimumab Demand, By Patient Population
4.5. Commonly Observed Side-Effects
4.6. Brand Awareness
5. Pharmacodynamic Overview of Adalimumab
5.1. Mechanism of Action
5.2. Absorption
5.3. Volume of Distribution
5.4. Route of Elimination
5.5. Half Life
5.6. Clearance
5.7. Toxicity
6. Clinical Trials
6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Clinical Trial Analysis
7. Patent Analysis
7.1. Patent Granted
7.2. Patent Applications Filed
8. Global Adalimumab Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Biologics v/s Biosimilars)
8.2.2. By Product Type (Branded v/s Generics)
8.2.3. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Others)
8.2.4. Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
8.2.5. By End User (Hospitals & Clinics, Home Healthcare, Others)
8.2.6. By Company (2022)
8.2.7. By Region
8.3. Product Market Map
9. North America Adalimumab Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product Type
9.2.3. By Therapeutic Area
9.2.4. By Distribution Channel
9.2.5. By End User
9.2.6. By Country
9.3. North America: Country Analysis
9.3.1. United States Adalimumab Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product Type
9.3.1.2.3. By Therapeutic Area
9.3.1.2.4. By Distribution Channel
9.3.1.2.5. By End User
9.3.2. Mexico Adalimumab Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product Type
9.3.2.2.3. By Therapeutic Area
9.3.2.2.4. By Distribution Channel
9.3.2.2.5. By End User
9.3.3. Canada Adalimumab Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product Type
9.3.3.2.3. By Therapeutic Area
9.3.3.2.4. By Distribution Channel
9.3.3.2.5. By End User
10. Europe Adalimumab Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product Type
10.2.3. By Therapeutic Area
10.2.4. By Distribution Channel
10.2.5. By End User
10.2.6. By Country
10.3. Europe: Country Analysis
10.3.1. France Adalimumab Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product Type
10.3.1.2.3. By Therapeutic Area
10.3.1.2.4. By Distribution Channel
10.3.1.2.5. By End User
10.3.2. Germany Adalimumab Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product Type
10.3.2.2.3. By Therapeutic Area
10.3.2.2.4. By Distribution Channel
10.3.2.2.5. By End User
10.3.3. United Kingdom Adalimumab Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product Type
10.3.3.2.3. By Therapeutic Area
10.3.3.2.4. By Distribution Channel
10.3.3.2.5. By End User
10.3.4. Italy Adalimumab Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Product Type
10.3.4.2.3. By Therapeutic Area
10.3.4.2.4. By Distribution Channel
10.3.4.2.5. By End User
10.3.5. Spain Adalimumab Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Type
10.3.5.2.2. By Product Type
10.3.5.2.3. By Therapeutic Area
10.3.5.2.4. By Distribution Channel
10.3.5.2.5. By End User
11. Asia-Pacific Adalimumab Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Product Type
11.2.3. By Therapeutic Area
11.2.4. By Distribution Channel
11.2.5. By End User
11.2.6. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Adalimumab Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Product Type
11.3.1.2.3. By Therapeutic Area
11.3.1.2.4. By Distribution Channel
11.3.1.2.5. By End User
11.3.2. India Adalimumab Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Product Type
11.3.2.2.3. By Therapeutic Area
11.3.2.2.4. By Distribution Channel
11.3.2.2.5. By End User
11.3.3. South Korea Adalimumab Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Transgenic Crop
11.3.3.2.2. By Technique
11.3.3.2.3. By Application
11.3.3.2.4. By End User
11.3.4. Japan Adalimumab Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Type
11.3.4.2.2. By Product Type
11.3.4.2.3. By Therapeutic Area
11.3.4.2.4. By Distribution Channel
11.3.4.2.5. By End User
11.3.5. Australia Adalimumab Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Type
11.3.5.2.2. By Product Type
11.3.5.2.3. By Therapeutic Area
11.3.5.2.4. By Distribution Channel
11.3.5.2.5. By End User
12. South America Adalimumab Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Type
12.2.2. By Product Type
12.2.3. By Therapeutic Area
12.2.4. By Distribution Channel
12.2.5. By End User
12.2.6. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Adalimumab Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Type
12.3.1.2.2. By Product Type
12.3.1.2.3. By Therapeutic Area
12.3.1.2.4. By Distribution Channel
12.3.1.2.5. By End User
12.3.2. Argentina Adalimumab Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Type
12.3.2.2.2. By Product Type
12.3.2.2.3. By Therapeutic Area
12.3.2.2.4. By Distribution Channel
12.3.2.2.5. By End User
12.3.3. Colombia Adalimumab Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Type
12.3.3.2.2. By Product Type
12.3.3.2.3. By Therapeutic Area
12.3.3.2.4. By Distribution Channel
12.3.3.2.5. By End User
13. Middle East and Africa Adalimumab Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value & Volume
13.2. Market Share & Forecast
13.2.1. By Type
13.2.2. By Product Type
13.2.3. By Therapeutic Area
13.2.4. By Distribution Channel
13.2.5. By End User
13.2.6. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Adalimumab Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Type
13.3.1.2.2. By Product Type
13.3.1.2.3. By Therapeutic Area
13.3.1.2.4. By Distribution Channel
13.3.1.2.5. By End User
13.3.2. Saudi Arabia Adalimumab Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Type
13.3.2.2.2. By Product Type
13.3.2.2.3. By Therapeutic Area
13.3.2.2.4. By Distribution Channel
13.3.2.2.5. By End User
13.3.3. UAE Adalimumab Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Type
13.3.3.2.2. By Product Type
13.3.3.2.3. By Therapeutic Area
13.3.3.2.4. By Distribution Channel
13.3.3.2.5. By End User
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. Competitive Landscape
16.1. Abbvie Inc.
16.2. Pfizer, Inc.
16.3. Amgen Inc.
16.4. Novartis AG
16.5. Torrent Pharmaceuticals Ltd.
16.6. Cadila Healthcare Limited
16.7. Boehringer Ingelheim International GmbH
16.8. Mylan N.V.
16.9. Hetero Biopharma Ltd
16.10. Samsung Bioepis Co Ltd.
17. Strategic Recommendations18. About Us & Disclaimer

Companies Mentioned

  • Abbvie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

Related Topics

Related Reports

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024 - Product Image

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Adalimumab Drugs Market Report and Forecast 2024-2032 - Product Image

Adalimumab Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From
Adalimumab Biosimilar Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Adalimumab Biosimilar Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Adalimumab (Humira) Biosimilars Pipeline Review - Product Image

Adalimumab (Humira) Biosimilars Pipeline Review

  • Report
  • Global
From
Ankylosing Spondylitis / AxSpA in the United States: Understanding the AS / AxSpA Patient Experience - Product Image

Ankylosing Spondylitis / AxSpA in the United States: Understanding the AS / AxSpA Patient Experience

  • Report
  • 138 Pages
  • United States
Copyright © 2002-2024 Research and Markets. All Rights Reserved.